ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 275 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 2.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,324 | -12.7% | 111,534 | +0.3% | 0.11% | -6.0% |
| Q2 2023 | $2,662 | -0.2% | 111,154 | -21.5% | 0.12% | -7.9% |
| Q1 2023 | $2,666 | -4.0% | 141,664 | -18.8% | 0.13% | -18.2% |
| Q4 2022 | $2,778 | -99.9% | 174,519 | -1.8% | 0.15% | -12.5% |
| Q3 2022 | $2,907,000 | +24.2% | 177,712 | +7.0% | 0.18% | 0.0% |
| Q2 2022 | $2,341,000 | -7.1% | 166,131 | +59.7% | 0.18% | +6.7% |
| Q1 2022 | $2,520,000 | +196.5% | 104,052 | +185.6% | 0.16% | +55.7% |
| Q4 2021 | $850,000 | +155.3% | 36,432 | +81.6% | 0.11% | +140.9% |
| Q3 2021 | $333,000 | -9.8% | 20,062 | +190.9% | 0.04% | -58.1% |
| Q4 2020 | $369,000 | +29.5% | 6,897 | 0.0% | 0.10% | +16.7% |
| Q3 2020 | $285,000 | -50.8% | 6,897 | -42.2% | 0.09% | -54.3% |
| Q2 2020 | $579,000 | -41.9% | 11,937 | -49.4% | 0.20% | -53.1% |
| Q1 2020 | $997,000 | +276.2% | 23,609 | +220.3% | 0.42% | +324.2% |
| Q3 2019 | $265,000 | – | 7,370 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |